Abstract: ［Abstract］〓Objective〖HTSS〗〓To investigate the efficacy and safety of lowdose anisodamine injection combined with tetramethylpyrazine injection in the treatment of patients with diabetic neuropathies.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Sixty patients with diabetic neuropathies were randomly divided into control group and treatment group, 30 cases in each group. The control group was treated with Mecobalamin and Epalrestat. The treatment group was treated with lowdose anisodamine and Tetramethylpyrazine injection in addition to the medicine used in the control group. The treatment lasted 2 weeks. The following data were used to compare the clinical efficacy of the two groups before and after treatment：the level of high sensitive C reaction protein(hsCRP); the score of the Toronto Clinical Scoring System(TCSS); the motor nerve conduction velocity(MNCV) of bilateral median nerve, common peroneal nerve, tibial nerve and the sensory nerve conduction velocity(SNCV) of median nerve, sural nerve.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After treatment, the hsCRP levels in both groups were significantly lower than those before treatment, and the hsCRP levels in the treatment group were significantly lower than those in the control group(P＜005). In both groups, the MNCV data of median nerve, the common peroneal nerve, the radial nerve and median nerve and the sural nerve were significantly higher than those before treatment, and the MNCV date of common peroneal nerve, tibial nerve and the SNCV data of median nerve, sural nerve were higher than those of control group(P＜005). The clinical efficacy of the treatment group was better than that of the control group, and the total effective rate was higher than that of the control group(P＜005). The TCSS scores of the two groups were significantly lower than those before treatment. The TCSS scores of the treatment group were lower than the control group(P＜005). The TCSS score of the treatment group was better than that of the control group, and the total effective rate was significantly higher than that of the control group(P＜005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The treatment of diabetic neuropathies with lowdose anisodamine combined with tetramethylpyrazine is relatively safe and costeffective, especially for grassroots patients with primary disease who have practical clinical significance in reducing drug costs and social security expenses.

Key words: diabetic neuropathies, anisodamine, tetramethylpyrazine